Hancock Jaffe Principal Investigator Dr Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Provided by Accesswire
Apr 23, 2021 4:40 PM UTC
IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.
Patients in the first-in-human study demonstrated significant improvement in all study endpoints including an aggregate 54% improvement in reflux (the backwards flow of blood), a 56% improvement in disease manifestations, as measured by venous clinical severity scores ( rVCSS ), and a 76% improvement in pain, as measured on a visual
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium April 23, 2021 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.
First U S Patent Issues on Hancock Jaffe VenoValve newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Hancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValve /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company s VenoValve. The patent is entitled
Implantable Vein Frame and is U.S. patent number 10,959,841.
The company recently announced that only twenty-eight (28) days after filing, the U.S. Food and Drug Administration (FDA) approved the company s Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the VenoValve®. Known as the SAVVE study, the trial is a prospective, non-blinded, single arm, multi-center study of 75 Chronic Venous Insufficiency (CVI) patients to be enrolled at up to 20 U.S. centers.